ArticleApplied and environmental microbiology2022
Evidence for Widespread Class II Microcins in
Article in Applied and environmental microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Prevalence and activity of class II microcins inApplied and environmental microbiology · 2026Article
- Refactored genetic parts for modular assembly of the E. coli MccV type I secretion system used to screen class II microcin candidates from plant-associated bacteria.BMC biotechnology · 2026Article
- Antibacterial microcins self-assemble to promote biofilm formation in Acinetobacter baumannii.Cell reports · 2026Article
- Heterologous expression and functional characterization of novel microcin B17 congeners from environmental Pseudomonas isolates.Applied microbiology and biotechnology · 2026Article
- Ec W: A Novel Narrow-Spectrum Class IIb Microcin from Escherichia coli.Probiotics and antimicrobial proteins · 2026Article
- Antibacterial microcins are ubiquitous and functionally diverse across bacterial communities.Nature communications · 2025Article
- Antibacterial action, proteolytic immunity, and in vivo activity of a Vibrio cholerae microcin.Cell host & microbe · 2024Article
- Semantic search using protein large language models detects class II microcins in bacterial genomes.mSystems · 2024Article
- Class IIb Microcin MccM Interferes with Oxidative Phosphorylation inACS chemical biology · 2024Article
- Escherichia coli has an undiscovered ability to inhibit the growth of both Gram-negative and Gram-positive bacteria.Scientific reports · 2024Article
- Proteases Involved in Leader Peptide Removal during RiPP Biosynthesis.ACS bio & med chem Au · 2024Review
- A comprehensive investigation of the medicinal efficacy of antimicrobial fusion peptides expressed in probiotic bacteria for the treatment of pan drug-resistant (PDR) infections.Archives of microbiology · 2024Article
- Semantic search using protein large language models detects class II microcins in bacterial genomes.bioRxiv : the preprint server for biology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Microcins are a class of antimicrobial peptides produced by certain Gram-negative bacterial species to kill or inhibit the growth of competing bacteria. Only 10 unique, experimentally validated class II microcins have been identified, and the majority of these come from Escherichia coli. Although the current representation of microcins is sparse, they exhibit a diverse array of molecular functionalities, uptake mechanisms, and target specificities. This broad diversity from such a small representation suggests that microcins may have untapped potential for bioprospecting peptide antibiotics from genomic data sets. We used a systematic bioinformatics approach to search for verified and novel class II microcins in E. coli and other species within its family,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.